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FcRI-Deficient Mice Show Multiple Alterations
to Inflammatory and Immune Responses
(see Results), which until now has been widely assumed
to be lacking in these mice (Hazenbos et al., 1996; Takai
et al., 1996; Vora et al., 1997).
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Australia high-affinity FcR binding IgG2a, a product of the adap-
tive Th1-type immune response, and it is also the recep-2 The Scripps Research Institute
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defined in mice (Gavin et al., 2000) and highly responsiveP.O. Box 1368
Canning Vale, Western Australia 6970 to IFN- (Hulett and Hogarth, 1994). Apart from receptor
binding studies, relatively little is known of the biologicalAustralia
functions of FcRI in either normal or pathological immu-
nity. The investigation of FcRI function has depended
on indirect or inferential studies using FcR- chain-defi-Summary
cient mice; thus, the contribution of FcRI to Fc-depen-
dent functions was not clear. Until now, mice specificallyThe inactivation of the mouse high-affinity IgG Fc re-
ceptor FcRI resulted in a wide range of defects in lacking FcRI alone have not been available and there
were no monoclonal antibodies specific for mouseantibody Fc-dependent functions. These studies
showed the primary importance of FcRI in endocyto- FcRI; thus, FcRI remains the least characterized of
the mouse FcR.sis of monomeric IgG, kinetics, and extent of phagocy-
tosis of immune complexes, in macrophage-based In this study of our FcRI/ mice, a number of surpris-
ing observations were made. It is obvious now that thisADCC, and in immune complex-dependent antigen
presentation to primed T cells. In the absence of FcRI, receptor is crucial for some of the earliest events in
immune responses, since receptor inactivation resultsantibody responses were elevated, implying the re-
moval of a control point by the deletion of FcRI. In in: (1) loss of uptake of immune complexes of the T cell-
independent immunoglobulin IgG3, as well as a pro-addition, FcR- chain-deficient mice were found to
express partially functional FcRI. Thus, FcRI is an found reduction in IgG2a uptake; (2) a 10-fold reduction
in antibody-dependent killing of cells by macrophages;early participant in Fc-dependent cell activation and
in the development of immune responses. (3) impaired FcR-dependent delivery of antigen in im-
mune complexes to antigen presentation pathways as
ten times more antigen in immune complexes is requiredIntroduction
for stimulation of T cells by FcRI/ APC than by normal
APC; (4) decreased immune complex-induced inflam-The receptors for immunoglobulins (Fc receptors, or
FcR) play important roles in the activation and regulation mation; and (5) enhancement of antibody responses.
of normal and pathological immunity. The IgG receptors
(FcR) comprise the largest family, encoding at least Results
ten membrane proteins in humans and five in mice (Hu-
lett and Hogarth, 1994). Virtually all of these belong to Disruption of the FcRI Gene
two low-affinity receptor groups, FcRII and FcRIII; A defective form of the FcRI gene was constructed from
however, both humans and mice also express a unique genomic DNA in which the promoter and transcription
high-affinity receptor, FcRI. initiation site, as well as the translation initiation codon
The investigation of Fc receptor function in vivo has ATG, were deleted. A neomycin resistance cassette was
depended heavily on “gene-knockout” mice and to a inserted into the second leader exon, resulting in disrup-
large extent on mice with a deletion of the common tion of this exon and the leader sequence, as well as
FcR- chain, shared by multiple activating Fc receptors generating a premature translation termination codon
(Ravetch and Bolland, 2001). While these mice have immediately downstream of exon 2 (Figure 1A). This
been useful, the simultaneous expression of multiple DNA construct incorporated a unique HindIII site to be
activating Fc receptors on cells, e.g., macrophages, used to distinguish correctly integrated target DNA (8.3
dendritic cells, neutrophils, and mast cells, and their kb) from the wild-type FcRI (9.7 kb) genomic DNA. W9.5
sharing of the common FcR- chain, has led to often ES cell clones positive for the targeted integration were
inconclusive or ambiguous results, particularly with in microinjected into C57BL/6 blastocysts, and a founder
vivo experiments. This is especially the case now that chimera was backcrossed to 129/SvJ mice. Animals ho-
FcR- chain mice have been shown to express FcRI mozygous for the FcRI null allele were identified by
Southern hybridization analysis of HindIII-digested ge-
nomic DNA isolated from the progeny of the founder4 Correspondence: pm.hogarth@ari.unimelb.edu.au
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Figure 1. Inactivation of the Mouse FcRI Gene
(A) Schematic representation of the mouse FcRI gene and the inactivation strategy. The restriction map of the wild-type allele (upper) and
inactivated allele (lower) are shown with exons represented as closed boxes. L1 and L2, leader region; EC1, EC2, and EC3, extracellular
domains; T/C, transmembrane and cytoplasmic tail. The restrictions sites are as follows: B, BamHI; S, SalI; E, EcoRI; and H, HindIII.
(B) Southern hybridization analysis of HindIII-digested genomic DNA isolated from the progeny of the founder mouse was probed with a 1.8
kb HincII/SacI fragment derived from the 5 end of the FcRI gene. Wild-type (/) mouse DNA had a hybridizing band of 9.7 kb, the receptor-
deficient mice (/) had a hybridizing band of 8.3 kb, and heterozygous animals (/) had both.
(C) Northern blots of total RNA extracted from bone marrow-derived macrophages (BMM) of normal (/) or receptor-deficient (/) mice.
BMM were also cultured for 24 hr in the presence or absence of IFN-. The blot was probed with FcRI cDNA, then reprobed with  actin
cDNA to ensure equal loading of mRNA in each lane.
(Figure 1B). FcRI / mice were fertile and showed Thus, these animals clearly lack FcRI as (1) they have
no FcRI mRNA even in the presence of IFN-; (2) theirno developmental abnormalities. Expression of FcRI
mRNA and protein was examined in bone marrow- macrophages are unable to bind the ligands of FcRI;
and (3) there is no binding of an anti-FcRI antibody toderived macrophages (BMM) from these mice. Northern
blots showed the 1.5 and 2.3 kb mRNA species in normal these macrophages.
but not in FcRI-deficient BMM, even following treat-
ment with IFN-, a potent inducer of receptor expression Loss of Endocytosis by FcRI-Deficient BMM
The capacity of BMM to internalize IgG was investigated(Figure 1C).
FcRI protein was absent from the surface of FcRI- by first pulsing BMM with monomeric mouse IgG2a fol-
lowed by subsequent crosslinking by goat anti-mousedeficient BMM, as these cells bound neither the specific
anti-FcRI monoclonal antibody (X54-5/7.1) nor two dif- IgG and internalization tracked using fluorescence mi-
croscopy (Figure 3). As expected, normal BMM boundferent monomeric ligands (mouse IgG2a and human
IgG), whereas binding to normal BMM was as expected. IgG2a showing ring staining on the outer cell membrane
in the absence of crosslinking antibody. Following theInactivation of the FcRI gene did not affect the expres-
sion of two other macrophage cell surface markers, de- addition of goat anti-mouse Ig, the receptor-bound
IgG2a was internalized, and after 20 min appeared intected by mAb F4/80 (specific for macrophages) and
2.4G2 (Figure 2). The 2.4G2 mAb recognizes a shared intracellular vesicles (Figure 3B). Identical results were
obtained using the BMM treated with the monoclonalepitope of FcRII and FcRIII, and expression was iden-
tical in BMM from both normal and FcRI-deficient mice. anti-FcRI antibody rather than IgG (data not shown).
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Figure 2. Expression of FcR by Normal and FcRI-Deficient BMM
Flow cytofluorometric analysis of FcRI and other cell surface markers of BMM from wild-type (dark lines) and FcRI-deficient (light lines)
mice. Expression of FcRI was tested using a specific anti-FcRI mAb, X54-5/7.1 (IgG1) or FcRI ligands, mouse IgG2a, and human IgG.
Expression of the macrophage-specific marker was detected with F4/80 mAb. The low-affinity receptors, FcRII and FcRIII, were detected
using the mAb 2.4G2. Background binding of the appropriate FITC-labeled anti-IgG conjugates (anti-mouse, -rat, or -human) Fab2 fragments
(dotted lines).
However, BMM lacking FcRI failed to bind monomeric no direct measurement, have consistently been re-
ported to lack FcRI (Hazenbos et al., 1996; Takai etIgG2a (Figures 2 and 3C) and did not internalize IgG
(Figure 3D), indicating that the uptake of monomeric IgG al., 1994, 1996). However, using anti-FcRI monoclonal
antibody (X54-5/7.1) and immunofluorescence analysisby macrophages is mediated only by FcRI.
of BMM from FcR- chain-deficient mice unexpectedly
revealed significant levels of FcRI expression, at aboutMice Deficient in the FcR- Chain
Express Functional FcRI 1/5 the level of the receptor expressed on normal macro-
phages. Most importantly, the receptor was functionalDuring the initial characterization of our FcRI-deficient
mice, we also analyzed cells of the FcR- chain-deficient and bound monomeric IgG2a (Figure 4A). The bound
IgG2a was internalized as for FcRI in normal BMMmice for control purposes. The FcR- chain is shared
by a number of Fc and other receptors (Ernst et al., (compare Figures 3 and 4B), although the intensity of
fluorescence was lower, being consistent with the re-1993; Ra et al., 1989), and mice deficient in FcR- chain
show a loss of FcRI and FcRIII expression and, despite duced receptor expression. Receptor internalization
Figure 3. Endocytosis of Mouse IgG2a by
BMM
Normal (A and B) and FcRI-deficient (C and
D) BMM were incubated with monomeric
IgG2a antibody at 4C for 60 min and then
incubated at 37C for 20 min in the absence
(A and C) and the presence (B and D) of cross-
linking Fab2 fragments of goat anti-mouse
IgG. Following incubation, the cells were
fixed, permeabilized, and incubated with
FITC-conjugated anti-goat IgG for 30 min and
viewed by fluorescence microscopy (original
magnification 400).
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Figure 4. Expression of FcRI by FcR- Chain-Deficient BMM
(A) Flow cytometry of FcR expression by BMM derived from normal (dark lines) and FcR- chain-deficient mice (light lines) was detected with
the anti-FcRI mAb X54-5/7.1, mouse IgG2a, or mAb 2.4G2. Background binding of FITC-labeled anti-IgG conjugates (anti-mouse or -rat)
Fab2 fragments is shown as dotted lines.
(B) Fluorescence micrographs of the endocytosis of monomeric IgG2a via FcRI from FcR- chain-deficient BMM. The cells were incubated
with IgG2a antibody at 4C for 60 min, then incubated at 37C for 20 min in the absence (no GAM Ig) or the presence ( GAM Ig) of crosslinking
Fab2 fragments of goat anti-mouse IgG. Following incubation, the cells were fixed, permeabilized, and incubated with FITC-conjugated anti-
goat IgG for 30 min (original magnification 400).
was also shown using Fab2 fragments of the anti-FcRI absence of FcRI suggests the involvement of FcRIII.
antibody (data not shown). Thus, these experiments This is consistent with the rate of uptake being equiva-
show that the high-affinity FcRI is still expressed and lent to IgG1-EA uptake via FcRIII (Figure 5C). Thus,
at least partly functional, with endocytosis able to occur on normal macrophages, endocytosis of soluble IgG
in BMM in the absence of the FcR- chain. or phagocytosis of particulate IgG occurs via different
mechanisms, and despite the continued expression of
FcRI in FcR- chain-deficient mice, phagocytosis ofSelective Impairment of Phagocytosis
IgG2a-EA could not occur, indicating the importancein FcRI/ BMM
of this ITAM-dependent pathway in phagocytosis. ThisMajor differences in the phagocytosis of immune com-
is consistent with previous reports on the importanceplexes of IgG2a and IgG3 but not IgG1 by FcRI-defi-
of the FcR- chain in phagocytosis (Takai et al., 1996).cient BMM were apparent (Figure 5). (1) IgG2a: The kinet-
(2) IgG3: The kinetics of uptake of IgG3-EA by normalics and extent of uptake of IgG2a complexes was
BMM was slower than that of IgG2a-EA, but the lossprofoundly impaired in FcRI-deficient BMM but was
of IgG3 phagocytosis was more dramatic than that ofnot entirely absent (Figure 5A). Normal macrophages
IgG2a-EA (Figure 5B). Uptake of IgG3-EA, a T cell-inde-rapidly phagocytosed IgG2a-opsonized SRBC (IgG2a-
pendent immunoglobulin, defined as a ligand for FcRIEA) at a rate of 400 SRBC per 100 BMM in 20 min to a
(Gavin et al., 1998a), was zero at all time points in themaximum of 1000 per 100 BMM by 40 min, which was
FcRI-deficient BMM, clearly confirming that FcRI isunaltered at 60 min (Figure 5A). This was more extensive
the only IgG3 receptor and that FcRII/FcRIII has noand rapid than IgG1-EA phagocytosis via FcRIII, where
involvement in IgG3 binding. These results also provideafter 60 min, only 300 SRBC were ingested (compare
useful controls and indicate that BMM did not “sponta-Figures 5A and 5C). However, in the absence of FcRI,
neously” engulf antibody-coated SRBC. (3) IgG1: As ex-BMM were able to ingest IgG2a-EA but at a greatly
pected, the phagocytosis of IgG1-EA by BMM fromreduced rate, ingesting fewer than 400 SRBC per 100
FcRI/ mice was indistinguishable from normal BMMBMM in 60 min, thus showing that FcRI provides a
since this IgG subclass does not bind to FcRI (Figuremechanism for the rapid uptake of complexes. It is clear
that the slower but significant uptake of IgG2a-EA in the 5C). However, it should be noted that the rate of uptake
Immune Defects in FcRI/ Mice
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SRBC (Figure 6A). Thus, ADCC in the absence of FcRI
but through FcRIII requires more antibody to achieve
the same level of killing, indicating a major role for FcRI
in macrophage ADCC. The differences in the quantity
of antibody required to achieve killing probably reflect
differences in the affinity of the high- and low-affinity
receptors for antibody.
Antigen Presentation Is Impaired
in FcRI/ BMM
The capacity of cells to present antigen following its
uptake in an immune complex was severely impaired in
cells lacking FcRI. Normal and FcRI-deficient BMM
were pulsed with human Ig (huIg) and their capacity to
stimulate CD4 T cells isolated from huIg primed mice
determined (Figure 6B). At low antigen concentration
(10 g/ml huIg), the FcRI-deficient BMM were unable
to induce T cell proliferation (1000 cpm) compared with
normal BMM where near-maximum stimulation (14,000
cpm) was achieved (Figure 6B). Furthermore, ten times
more antigen (100 g/ml compared to 10 g/ml) was
required by the FcRI-deficient BMM in order to stimu-
late T cell proliferation equivalent to that obtained by
normal BMM. The differences in the affinity between
FcRI and FcRIII are likely to account for the difference
in immune complex-dependent antigen presentation
between normal and FcRI-deficient BMM. Thus, at low
immune complex (antigen) concentration and in the ab-
sence of FcRI, macrophages expressing FcRII and
FcRIII were unable to bind and present antigen effi-Figure 5. Kinetics and Specificity of Uptake of Immune Complexes
ciently. Clearly then, FcRI is required for optimal anti-by BMM
gen presentation through this pathway.Ingestion of erythrocytes sensitized with mouse IgG2a (A), IgG3 (B),
or IgG1 (C) by BMM from FcRI/ (hatched), FcRI/ (black), and
FcR- chain/ (gray) mice. The number of erythrocytes ingested FcRI/ Mice Have Reduced
per 100 BMM represented the uptake of complexes after 20, 40, Inflammatory Responses
and 60 min incubation. There was no uptake (	5 erythrocytes/100
FcR have a major role in immune complex-induced vas-BMM) in the absence of sensitizing antibody. Results are expressed
culitis and inflammation, and it has recently been re-as the mean of three experiments; standard errors of the mean
were 	10%. ported that the use of soluble FcR proteins and/or in-
activation of low-affinity FcR genes can reduce
inflammation (Hazenbos et al., 1996; Ierino et al., 1993;
was considerably slower than that of IgG2a-EA as men- Sylvestre and Ravetch, 1996). We examined the inflam-
tioned above. This result also indicates that there is no matory response in vivo in the FcRI/ mice using a
“global” defect in phagocytic pathways in the FcRI- reverse passive Arthus model (Figure 6C). The induction
deficient BMM. No phagocytosis above background lev- of inflammation, measured by footpad swelling after lo-
els was seen with BMM from the FcR- chain/ mice cal deposition of antibody in the presence of high levels
following a 1 hr incubation with IgG1-EA. of circulating antigen, indicated that the loss of FcRI
results in alterations to both the kinetics and the magni-
tude of the Arthus reaction but not its complete ablation.Reduced Antibody-Dependent Cell-Mediated
Cytotoxicity by FcRI/ BMM The Arthus reaction in the wild-type mice peaked at
approximately 3–5 hr with a steady decline over theFcR play a major role in the killing of antibody-coated
target cells (Fanger et al., 1989). This function has been ensuing 20 to 24 hr. This was typical of the kinetics seen
in a number of experiments. By contrast, the Arthuslargely attributed to FcRIII (Takai et al., 1994) and analy-
sis principally focused on NK cells (Hazenbos et al., reaction measured in the FcRI/ mice was slower to
develop and, while it peaked at 5 hr, showed a maximum1996). However, macrophages participate in antibody-
dependent cell-mediated cytotoxicity (ADCC) and ex- increase in swelling that was 70% of that observed in
the wild-type mice. Moreover, the inflammation resolvedpress both FcRI and FcRIII, but the specific roles of
these receptors in ADCC have not been defined. BMM more rapidly, returning to background by approximately
8 hr (Figure 6C). This reaction was specific, as no inflam-expressing both FcRI and FcRIII in wild-type mice
were potent effector cells (Figure 6); however, BMM mation was detected in the absence of ovalbumin nor
in the absence of ovalbumin-specific IgG. It is clearlacking FcRI but expressing unchanged levels of
FcRIII (see Figure 2) were considerably less efficient, therefore that the high-affinity IgG receptor also plays
a role in the generation of immune complex-inducedwith the loss of FcRI resulting in a reduction of between
30%–60% in antibody-dependent cell-mediated lysis of inflammation; the presence of FcRII and FcRIII (the
Immunity
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Figure 6. Antibody-Dependent Cell-Mediated Cytotoxicity, Antigen Presentation by BMM, and Arthus Reaction In Vivo
(A) ADCC of 51Cr-labeled SRBC by BMM from FcRI/ (closed squares) and FcRI/ (open circles) mice at a range of concentrations of anti-
erythrocyte antibody and an E:T ratio of 1:1. Results are expressed as a percentage of specific lysis in four individual experiments 
SEM.
(B) FcRI-deficient mice showed impaired antigen presentation. Irradiated spleen APCs from FcRI/ (open circles) and FcRI/ (closed
squares) mice were cultured with antigen-specific T cells and incubated with a range of antigen (human IgG) concentrations. T cell proliferation
was measured by 3H-thymidine uptake. The level of proliferation induced by anti-CD3 mAb alone is indicated by the dashed line. Results are
expressed as the mean of three individual experiments 
SEM.
(C) FcRI-deficient mice have impaired inflammation. Immune complex-induced inflammation was determined in the footpad using a reverse
passive Arthus reaction induced by OVA/anti-OVA complexes. The extent of inflammation was determined by measurement of swelling in the
footpad of FcRI/ (closed circles) and FcRI/ (open circles) mice. Specificity of the Arthus reaction was determined by injection of
nonimmune IgG in the presence of antigen in FcRI/ (closed squares) and FcRI/ (open squares) mice. Results are expressed as the
mean of three individual experiments 
SEM. There were three mice per experimental group.
low-affinity immune complex receptors) could not com- in antibody-forming cells for both IgM and IgG compared
to those of normal mice (Figure 7B). Antibody half-lifepensate for the loss of FcRI.
in the FcRI/ mice was not different from FcRI/
mice (data not shown). Thus, FcRI appears to play aIncreased IgG Responses in FcRI/ Mice
key role in the modulation of antibody responses in vivo,Antibody production was investigated in both wild-type
and deletion results in an increase in the number ofand FcRI-deficient mice using NP-KLH as antigen.
antibody-forming cells.Mice were immunized, then NP-specific IgG1, IgG2a,
IgG2b, and IgG3 were determined for individual mice 14
days after immunization (Figure 7A). Compared to wild- Discussion
type mice, FcRI/ mice showed 2- to 5-fold increases
in the levels of IgG subclasses following immunization. The inactivation of the gene encoding the unique high-
affinity Fc receptor—FcRI—resulted in a wide range ofThis was most noticeable for IgG2b, IgG3, and IgG1;
IgG2a was less marked although the difference was defects in antibody Fc-dependent effector cell function,
as well as elevated antibody production in vivo. Thestatistically significant (p	 0.05). Thus, the lack of FcRI
resulted in a generalized increase in IgG levels. The studies presented herein showed that FcRI is far more
effective than other FcR in initiating endocytosis ofnumber of antibody-forming cells induced following im-
munization was determined in a modified hemolytic soluble IgG, phagocytosis of immune complexes, anti-
body-dependent killing of cells, and the delivery of im-plaque-forming cell assay. Spleens of FcRI/ mice
immunized with SRBC showed a 2- to 3-fold increase mune complexes to antigen presentation pathways. In
Immune Defects in FcRI/ Mice
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Figure 7. FcRI-Deficient Mice Have an Increased Antibody Production
(A) FcRI/ (open circles) and FcRI/ (closed squares) mice were immunized with 100 g of NP-KLH i.p., and serum Ig titres were determined
at day 14 postimmunization. Symbols represent antibody titre from individual mice. The mean titre of each experimental group of 12 mice is
represented as a bar; * indicates p 	 0.05.
(B) Plaque assays were performed on FcRI/ (hatched) and FcRI/ (black) mice immunized i.v. with SRBC. The number of plaques forming
cells per 106 spleen cells  52/3  number of plaques per chamber/5. Results were expressed as the mean of three experiments 
 SEM.
addition, in vivo inflammation was reduced and, interest- functions, especially given the role of immune com-
plexes in modifying antibody responses in vivo and iningly, antibody production was increased 2- to 5-fold
over normal mice. particular as the delivery of immune complexes to the
class II antigen presentation pathway occurs in the ab-Defining the role of the least studied Fc receptor, the
high-affinity IgG receptor FcRI, in antibody-dependent sence of functional FcR- chain, albeit with reduced
efficiency (van Vugt et al., 1999).effector functions and in immune responses in vivo has
been confounded by the lack of mice deficient in only The analysis of mice deficient only in FcRI has en-
abled us to understand the independent role of thisFcRI. Indeed, to date no direct analysis of FcRI has
been possible. Much of the current “understanding” has receptor in antibody-dependent systems, and there are
a number of key observations arising from the studiesbeen inferred largely from indirect analysis of FcR-
chain-deficient mice (Sylvestre and Ravetch, 1996; Takai presented herein.
The uptake of small or soluble immune complexes oret al., 1994, 1996; Vora et al., 1997) and to some extent
from other Fc receptor-deficient mice (Hazenbos et al., IgG requires different cell-based mechanisms to those
involved in phagocytosis. The uptake of soluble IgG is1996). One of the major difficulties with such analyses
is the widespread distribution of FcR- chain and its clearly mediated by FcRI, not the low-affinity receptors,
presumably by virtue of the differences in affinity be-promiscuous interactions with multiple receptors—
FcRI, FcRIII, FcRI, and the CD3 complex. Attempts tween FcRI and FcRII, or FcRIII. The process of en-
docytosis does not require FcR- chain as discussedto minimize the ambiguity in interpretation of data from
such mice include the use of different IgG subclasses, above and is clearly independent of the ITAM/tyrosine
kinase pathway necessary for processes such as phago-especially IgG2a, as specific probes for different recep-
tors. This has only confounded the problem, as it is cytosis (see Figures 3 and 4) (Takai et al., 1994).
The phagocytic uptake and destruction of particulateclear that receptor specificity is not as strict as often
assumed; i.e., IgG2a binds in complexes to FcRI, immune complexes is an important mechanism of resis-
tance to infection and is an important role of FcR gener-FcRII, and FcRIII (see Figure 5A) (Hogarth et al., 1985;
Hulett et al., 1991) . ally. The comparison of normal and FcRI-deficient
BMM showed that FcRI is the major IgG2a receptorThus, the studies shown herein show (1) the widely
held view that FcR- chain-deficient mice lack FcRI and provides the most rapid and extensive uptake of
immune complexes. FcRI is clearly more efficient than(Hazenbos et al., 1996; Takai et al., 1994, 1996) is clearly
not correct, the presence of the receptor confirmed both the low-affinity receptors even for highly opsonized
SRBC, which efficiently engage the FcRII and FcRIII.by ligand binding studies and the use of specific mono-
clonal anti-receptor antibodies; (2) although some FcRI IgG2a binding and phagocytosis still occur in the ab-
sence of FcRI, presumably through FcRIII where thefunctions (phagocytosis) are impaired due to lack of the
FcR- chain, endocytosis of IgG remains intact, which kinetics of uptake of IgG2a and IgG1 complexes is al-
most identical (Figure 5, note difference in scales). Anwas also confirmed by the use of receptor-specific
monoclonal antibodies. Clearly, this has implications for interesting practical observation is that IgG2a is often
used as a specific probe for FcRI, especially in theFcR-dependent antigen presentation and other in vivo
Immunity
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analysis of other FcR-deficient mice, and although zenbos et al., 1996; Takai et al., 1994), with FcRIIb
(Takai et al., 1996) acting as a regulator of the response.FcRII/FcRIII do not detectably bind monomeric IgG2a,
they clearly bind IgG2a complexes (Figure 5) (Hulett and Immune complexes are well-known to influence im-
mune responses (Heyman, 2000). Immunization of miceHogarth, 1994; Hulett et al., 1991; Unkeless and Eisen,
1975). lacking FcRI resulted in 2- to 5-fold increases in primary
antibody responses in vivo, which was reflected in anOn macrophages, both FcRI and FcRIII are ex-
pressed and active in ADCC (Figures 2 and 6A), but increase in the numbers of antibody-producing cells
(Figure 7). These data indicate that FcRI has a role inFcRI is more effective at lower antibody concentration
and presumably is more important earlier in humoral the regulation of antibody responses and suggest that
in the absence of FcRI, a control point is bypassedresponses when the concentration of circulating anti-
bodies is low, with FcRIII becoming increasingly impor- either by default or as an active process. Such a role
was suggested by the 30-year-old work of Parish andtant as antibody concentrations rise. To date, the analy-
sis of ADCC has focused on FcRIII and NK cells coworkers (Liew and Parish, 1972) who showed that
cytophilic IgG, which by definition bound to FcRI, could(Hazenbos et al., 1996; Takai et al., 1994; Vora et al.,
1997) using FcR- chain and/or FcRIII-deficient ani- modulate humoral and cellular responses. There are also
a series of additional observations that are consistentmals, and little analysis of macrophage ADCC has been
performed. The studies of others using FcR- chain- with a regulatory role for FcRI in antibody responses.
Indeed, exaggerated antibody responses and elevateddeficient mice show a complete ablation of ADCC
(Clynes et al., 1998), which, taken together with the anal- levels of circulating Ig have been observed in other
mouse strains with deletions of the cytoplasmic tail ofysis herein, is consistent with FcRI and FcRIII being
involved in macrophage ADCC, but clearly these recep- FcRI but with intact FcR- chain. These mouse strains
include Biozzi “high responder” mice bred for enhancedtors would be engaged at different times in a developing
immune response. antibody production and the NOD mice, which have
abnormal levels of IgG1 and IgG2b, but IgG2a is lessThe uptake of small complexes by FcRI-deficient
BMM for antigen presentation to primed T cells was affected, similar to the findings in the FcRI/ mice
herein (Gavin et al., 1998b; Luan et al., 1996; Regnaultstudied herein. These macrophages express all the
other fully functional Fc receptors, including the FcR- et al., 1999). The deletions in the cytoplasmic tail of
FcRI have been analyzed in transfection models andchain, in their normal cellular environment unlike studies
using transfected cells that never normally express shown to affect the intracellular handling of immune
complexes bound by FcRI and subsequent antigenthese receptors. The data (Figure 6B) show clear evi-
dence that at lower antibody concentrations, FcRI is presentation, independent of the FcR- chain (Gavin et
al., 1998b; van Vugt et al., 1999). It is interesting thenextremely efficient in uptake of immune complexes for
subsequent antigen presentation. Indeed, the capture that analysis by others of FcR- chain-deficient mice
(Clynes et al., 1998; Vora et al., 1997), which we nowof antigen in immune complexes and its subsequent
presentation is reduced by 70% by deletion of FcRI. know to express lower quantities of FcRI, showed no
consistant increase in antibody production. However,Over ten times more antigen (human IgG) is required to
achieve the same level of stimulation when complexes there were suggestive although inconclusive changes
in antibody responses in the study by Vora et al. (1997);are taken up via the low-affinity receptors in the absence
of FcRI; i.e., other FcR inefficiently deliver antigen in these may relate to the reduced but not absent expres-
sion of FcRI.immune complexes to antigen presenting pathways.
Autoimmune or other pathological immune responses The mechanism by which FcRI participates in the
development of antibody responses is not clear; how-often produce immune complexes that initiate destruc-
tive inflammatory responses. The cutaneous reverse ever, FcRI has several unique properties that enable
early participation in immune responses. It is the low-passive Arthus reaction is an in vivo model for immune
complex disease, featuring local tissue destruction by affinity receptor for the T cell-independent immunoglob-
ulin IgG3 and the high-affinity receptor for IgG2a, theantibody-mediated inflammatory responses, with mac-
rophages and neutrophils recruited to the site of inflam- archetypal antibody product of the Th-1 response, and
it does not bind IgG1, the archetypal antibody productmation. The independent role of FcRI has not been
reported previously, but our data indicate that the Arthus of the Th-2 response, which is preferentially bound by
the low-affinity Fc receptors. The switch from IgM toreaction in the FcRI/ mice was less severe than in
normal mice. The high-affinity IgG receptor therefore IgG3 can occur without T cell help and requires IFN-
provided by the innate immune system. The productionplays a role, possibly through efficient capture of anti-
body at inflammatory sites, in enhancing this immune of IFN- would also be expected to simultaneously
upregulate FcRI (Hulett and Hogarth, 1994). As thecomplex-induced inflammation; however, the presence
of the low-affinity receptors FcRII and FcRIII could not adaptive immune response develops, especially the
IFN--dependent Th-1 response, IgG2a, the high-affinityfully compensate for the loss of FcRI. This is consistent
with previous studies defining a major role of FcR in this ligand, is produced, thereby linking ligand production
to receptor upregulation and the innate and adaptiveresponse first indicated by the use of soluble recombi-
nant FcR that inhibited the Arthus reaction (Ierino et al., immune responses. In a Th-2 response, the IgG1 pro-
duced by the adaptive immune system would not en-1993). Subsequent studies with complement-deficient
mice and other FcR knockout mice have shown that the gage FcRI and presumably would have little effect on
responses until the concentrations of immune com-response is largely complement independent but mast
cell dependent and downregulated in FcR- chain and plexes rise sufficiently to engage the low-affinity recep-
tors. Thus, the early engagement of FcRI at the inter-FcRIII-deficient mice (Sylvestre and Ravetch, 1996; Ha-
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Bone Marrow-Derived Macrophagesface of innate and adaptive immunity, when IgG2a
Bone marrow-derived (BMM) stem cells were obtained from theconcentrations are low, may well provide a control point
femurs of mice and cultured in RPMI 1640 (CSL Biosciences, Austra-for Th-1 type responses. In such a model, the loss of
lia) and 30% L cell conditioned medium (LCM) for 4 days. Nonadher-
FcRI may result in the continued development of anti- ent cells were then harvested and cultured for a further 4 days until
body responses, particularly as other immune complex- confluent. For some assays, BMM were cultured for a further 24 hr
in the presence or absence of 100 U IFN- (Genzyme, USA) (Gavindependent regulatory pathways such as the coen-
et al., 1996).gagement of activating ITAM-dependent FcR with the
negative regulatory FcRIIb (Ravetch and Bolland, 2001;
Northern Blot AnalysisTakai et al., 1994) would not efficiently occur until anti-
Total RNA was extracted from BMM using RNAzol (GIBCO, USA)body concentrations in immune complexes had risen to
according to the manufacturer’s protocol. 10g of RNA was electro-
levels that would effectively engage FcRIII. The timing phoresed on a formaldehyde-agarose (1%) gel and transferred to
of the coengagement of the negative regulating FcRIIb Hybond Nmembrane (Amersham, Life Sciences, USA) and probed
with 32P-labeled 1.3 kb FcRI cDNA fragment. The membrane waswith the activating receptors may well be critical in con-
washed twice in 0.2 SSC, 1% SDS at 65C for 30 min and exposedtrolling activities such as antigen presentation and
overnight to Kodak XAR5 film (Kodak, Eastman, USA). The relativetherefore the overall response.
amounts of RNA were checked by reprobing with  actin cDNA toThe enhanced antibody production in vivo (Figure 7)
ensure equal loading of RNA in each lane.
but reduced antigen presentation in vitro (Figure 6C) by
BMM appears paradoxical. However, it should be noted Flow Cytofluorometric Analysis
that primed T cells were used in the antigen presentation Flow cytometric analysis of BMM was carried out using a Facscali-
bur flow cytometer (Becton-Dickinson). Expression of FcRI wasexperiments whereas the primary antibody response
tested using a specific anti-FcRI mAb, X54-5/7.1 (IgG1) (P.S.T.,was examined in vivo. Clearly, the stimulation of primed
unpublished data) or FcRI ligands, mouse (anti-TNP mAb) IgG2a,T cells is more readily achieved by immune complex
and human IgG (pooled IgG) (Novartis, Switzerland). Macrophages
uptake via FcRI than via the low-affinity receptors. were detected with the specific antibody F4/80, and the low-affinity
However, in naive mice, FcRI may be involved early in IgG receptors, FcRII and FcRIII, were detected using the 2.4G2
the development of the immune response, as well as antibody (Unkeless, 1979). Expression of all markers was compared
to background binding of the appropriate FITC-labeled anti-IgG con-having a later role in enhancing stimulation of primed
jugates (anti-mouse, -rat, or -human) Fab2 fragments.T cells.
Finally, it is clear that FcRI is of primary importance
Endocytosis Assayin many Fc-dependent effector cell functions, and while
FcRI-mediated internalization of IgG was examined using a modifi-
the basis for the elevated antibody responses it still cation of a previously described method (Harrison et al., 1994). BMM
uncertain, it is clear in vivo that FcRI receptor inactiva- were isolated from FcRI/, FcRI/, and FcR- chain/ mice
tion or mutation is correlated with altered antibody re- and allowed to attach in eight-well chamber slides (NUNC, Sweden).
The cells were then incubated with 10 g/ml of anti-FcRI (X54sponses.
-5-7.1) Fab2 or 10 g/ml of whole IgG2a for 60 min at 4C, washed
in 0.5%BSA in PBS, and then incubated in the presence or absence
Experimental Procedures of 50 g/ml crosslinking antibody (goat anti-mouse IgG, Fab spe-
cific) (Silenus, Australia). The slides were returned to 4C or warmed
Engineering of the FcRI Null Allele and Its Detection to 37C for 20 min. The cells were washed, fixed in 3% paraformalde-
A genomic clone of mouse FcRI gene was isolated from  Fix II hyde in 80 mM K2PIPES for 5 min followed by 3% paraformaldehyde
genomic library of 129/J DNA. A defective form of the FcRI gene in 100 mM Na2B4O7 for 10 min, and permeabilized in 0.1% Triton-X
was constructed by deleting the promoter and also disrupting the 100 (BDH chemicals, Australia) for 10 min. The internalized IgG was
coding region. First, a 400 bp segment of the 5 end of the gene detected with FITC-conjugated anti-mouse or anti-goat antibody
was deleted using splice overlap extension PCR. This deletion re- (Silenus, Australia) following incubation for 30 min at 37C, then
moved part of the promoter and the transcription initiation site, as visualized using confocal microscopy (Optiscan, Australia).
well as the translation initiation ATG. Secondly, a neomycin resis-
tance gene was inserted into the second leader exon, resulting in Phagocytosis Assay
the disruption of this exon and the leader sequence, as well as Immune complexes of IgG-sensitized sheep erythrocytes (EA) using
the generation of a frame shift mutation. This induced a premature IgG known isotype were generated as follows. SRBC were sensitized
termination codon immediately downstream of exon 2 (Figure 1A). by incubation with 2,4,6 trinitrobenzene sulphonic acid (TNBS) (Hu-
A unique HindIII site was used to distinguish correct integration of lett et al., 1991), then sensitized with monoclonal anti-TNP antibod-
the targeting DNA (8.3 kb) from the wild-type FcRI (9.7 kb) genomic ies, IgG3, IgG2a, or IgG1. Phagocytosis assays were performed
DNA (Figure 1B). Following electroporation of this DNA into W9.5 using monolayers of BMM which were incubated with 2% EA for
embryonic stem (ES) cells, and selection, 480 clones were screened various times from 10 to 60 min at 37C. The monolayers were then
by genomic Southern blots (Barnett and Kontgen, 2001; Kontgen washed to remove unattached EA, and surface-bound EA were lysed
and Stewart, 1993) and probed with a 1.8 kb HincII/SacI fragment by brief hypertonic shock (PBS, 1 mM NaCl [pH 2.5]), then fixed
derived from DNA 5 of the FcRI gene. Four clones that had under- in 0.5% glutaraldehyde. Ingested EA were visualized using light
gone homologous recombination were identified, from which two microscopy. The uptake of complexes was represented by the num-
were microinjected into C57BL/6 blastocysts. ber of EA ingested per 100 BMM at each time point. There was no
uptake (	5 EA/100 BMM) in the absence of sensitizing antibody.
Results are expressed as the mean of three individual experiments.Mice
The founder chimeric mouse was crossed to 129/SvJ mice, and
genomic DNA from subsequent progeny was isolated and screened Antibody-Dependent Cellular Cytotoxicity
Cytotoxicity assays were carried out in 96-well V-bottomed tissueby Southern hybridization for the presence of the FcRI null allele.
Homozygous animals contained either the wild-type “” 9.7 kb allele culture plates with 2  105 target cells (SRBC) labeled with 100
Ci 51Cr for 60 min at 37C in medium (RPMI 1640). The target cellsor the 8.3 kb “” inactivated allele (/ or /, respectively). Het-
erozygous animals are shown in figures as “/.” FcR- chain- were washed several times and incubated for 10 min at 37C with
rabbit anti-SRBC antibody at various concentrations. The cells weredeficient mice (FcR- chain/) were obtained from Dr. J. Ravetch
(Takai et al., 1994). mixed with effector cells (BMM) at various effector-to-target (E:T)
Immunity
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